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Background. +e age of candidates for device closure of atrial septal defect (ASD) has been increasing. +us, concerns exist about
dyspnea aggravation or atrial fibrillation development after device closure due to augmentation of left ventricular (LV) and left atrial
(LA) preload.+is study aimed to examine patterns and determinants of serial pulmonary arterial pressure and left ventricular filling
pressure changes after device closure of ASD. Methods. Among the 86 consecutive patients who underwent percutaneous device
closure of ASD, those with end-stage renal disease or those without pre- or postprocedural Doppler data were excluded.+e clinical,
transesophageal, and transthoracic echocardiographic findings of 78 patients were collected at baseline, one-day postprocedure, and
one-year follow-up.Results.+emean age of study patients was 49.8± 15.0 years, and the averagemaximal defect diameter and device
size were 20.2± 6.0mm and 23.8± 6.4mm. Four patients (5.6%) underwent new-onset atrial fibrillation, and five patients (6.4%) took
diuretics within one-year after closure. Some patients (n� 21; 27%) exhibited paradoxically increased tricuspid regurgitant velocity
(TRV) one-day postprocedure; they also were older with lower e’, glomerular filtration rate, and LV ejection fraction and a higher LA
volume index. However, even in these patients, TRV deceased below baseline levels one-year later. Both E/e’ and LA volume index
significantly increased immediately after device closure, but all decreased one-year later. Larger defect size and higher TRV were
significantly correlated with immediate E/e’ elevation. Conclusion. In older, renal, diastolic, and systolic dysfunctional patients with
larger LA and scheduled for larger device implantation, peri-interventional preload reduction therapy would be beneficial.
1. Introduction
+e age of candidates for device closure of atrial septal
defect (ASD) has been increasing. Especially in older
patients, concerns exist about dyspnea aggravation [1] or
atrial fibrillation development after device closure due to
the augmentation of left ventricular (LV) and left atrial
(LA) preload [2, 3]. Although recent studies showed that
the long-term outcome of device closure is quite good
even in older patients, vulnerable patients must be
identified to prepare them for periprocedural preload
reduction management. +us, in this study, we sought to
examine serial hemodynamic changes, including
pulmonary arterial systolic pressure, LV filling pressure,
stroke volume, and LA volume, after device closure of
ASD. In addition, factors contributing to adverse he-
modynamic changes from immediately after the proce-
dure to one-year follow-up were determined.
2. Materials and Methods
2.1. Study Population and Clinical Follow-Up. +e database
of a single center of patients who underwent percutaneous
device closure of ASD was analyzed. Patients underwent
transthoracic echocardiography (TTE) and trans-
esophageal echocardiography (TEE) before the device
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closure procedure. Among the 86 consecutive patients who
underwent percutaneous device closure of ASD, patients
with end-stage renal disease or patients without pre- or
postprocedural Doppler data were excluded. In total, the
clinical, transesophageal, and transthoracic echocardio-
graphic findings of 78 patients were collected at baseline,
one day (immediately) after the procedure, and one-year
follow-up (Figure 1). All patients underwent blood
chemistry and cell blood count analysis. Estimated glo-
merular filtration rate (eGFR) was calculated using the
Chronic Kidney Disease Epidemiology Collaboration
creatinine equation [4]. Clinical characteristics, medical
history, laboratory findings, medications, and echocar-
diographic data were collected and used for analysis. +e
study protocol was approved by the institutional review
board of Gangnam Severance hospital (3-2020-0026), and
the need for written informed consent was waived due to
the study’s retrospective design.
2.2. Echocardiography at Baseline and after Device Closure.
Each patient underwent a complete standard TTE. TTE
findings were collected at baseline, one-day (immediately)
postclosure, and one-year follow-up. LV dimensions and
septal and posterior wall thickness were measured at end-
diastole and end-systole in the two-dimensional (2D) par-
asternal long- or short-axis views. LV ejection fraction was
calculated using the modified Quinones’ method [5]. LV
mass was measured by Devereux’s methods as recom-
mended by the American Society of Echocardiography [5].
LA volume was measured using the prolate ellipsoidal
method at the point of LV end-systole at maximum LA size.
From the apical window, a 1mm pulsed Doppler sample
volume was placed at the mitral valve tip, and mitral flow
velocities from 5–10 cardiac cycles were recorded. Peak early
(E) and late (A) mitral inflow velocities were also measured.
Mitral annular velocity was measured by tissue Doppler
imaging using the pulsed-wave Doppler mode.+e filter was
set to exclude high-frequency signals, and the Nyquist limit
was adjusted to a range of 15–20 cm/s. Gain and sample
volume were minimized to allow for a clear tissue signal with
minimal background noise. Systolic (S’) and early (e’) and
late diastolic velocities of the mitral annulus were measured
from the apical four-chamber view with a sample volume
(2–5mm) placed at the septal corner of the mitral annulus.
Peak velocity of tricuspid regurgitation was measured.
Pulmonary arterial systolic pressure (PASP) was calculated
as follows: 4× tricuspid regurgitant velocity (TRV)2 + right
atrial pressure, where right atrial pressure was estimated
according to inferior vena cava diameter and its respiratory
variations [6]. E/e’ divided by stroke volume was defined as
LV end-diastolic elastance index [7]. During TEE, multi-
plane 2D and zoomed 3D images were acquired, and both
long- and short-axis diameters of the ASD were measured.
Area was calculated as long-axis diameter multiplied by
short-axis diameter and 3.14. In multiple defects, the sum of
all diameters or areas was used. +e margins to the aorta,
posterior wall, superior vena cava, and inferior vena cava
rims were also evaluated.
2.3. Device Implantation and Periprocedural Imaging.
Transcatheter ASD closure was performed, as described
previously [8], using various types of septal occluders
(Amplatzer/Cocoon/Figullar Flex II/Gore-Helix/Occlu-
tech). Before the procedure, the pulmonary-to-systemic
blood flow ratio and pulmonary artery pressure were
evaluated using cardiac catheterization. During the
procedure, 3D-TEE or intracardiac echocardiography
(ICE) were performed to guide accurate device implan-
tation and ensure successful device closure. After the
procedure, all patients received 100mg/day aspirin for at
least 6 months and 75mg clopidogrel for 3 months. Other
medications, such as diuretics and antihypertensive
medications, were continued.
2.4. Statistical Analysis. Clinical characteristics and echocar-
diographic parameters are presented as the means± standard
deviation for continuous variables and the numbers (percent-
age) for categorical variables. Correlation analysis was per-
formed between continuous variables using the Pearson
correlation coefficient. Comparisons of clinical and echocar-
diographic findings between two groups were performed using
the independent t-test. Nonparametric comparisons of two
groups were done by Mann–Whitney U test. Serial changes in
echocardiographic parameters were assessed using repeated
ANOVA or the paired t-test. Variables with P values less than
0.05 in univariate analysis were included in the multivariable
linear or logistic regression analysis. All the analyses were
performed using SPSS (version 25.0, IBM, USA), and P values
less than 0.05 were considered significant.
3. Results
3.1. Baseline Characteristics, Echocardiographic Parameters,
and Hemodynamic Findings. +e mean age of enrolled
patients was 49.8± 15.0 (range, 16–77) years, and 51 (65%)
were female. +e average body mass index was 22.5± 3.0 kg/
m2, and the average eGFR was 99.4± 20.0mL/min. Mean LV
ejection fraction and LV mass index were 66.1± 6.4% and
63.3± 16.3 g/m2, respectively. Among them, 4 patients had
more than one defects. Measured average defect maximal
diameter was 20.2± 6.0mm, and defect area was
2.57± 1.52 cm2 on preprocedural TEE.+e calculated Qp/Qs
ratio during right side catheterization before device im-
plantation was 2.52± 0.85. Sixty-four patients underwent
TEE, and 14 patients underwent ICE for periprocedural
guidance. +e average size of the septal occluder was
23.8± 6.4mm. Baseline characteristics are described in
Table 1.
3.2. Clinical Problems after Device Closure. Six patients had
history of persistent atrial fibrillation or documented
paroxysmal atrial fibrillation. Among the rest (n � 72),
four patients (4/72, 5.6%) underwent newly developed or
detected atrial fibrillation within one year after device
closure. Although it is not statistically significant due to
small number of the patients, the patients with new-onset
atrial fibrillation after closure had tendency of older age,
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lower eGFR, e’, and LV ejection fraction, and larger defect
size, LA volume index, and E/e. We could not find a case
with development of significant pulmonary edema;
however, five patients underwent taking diuretics after
device closure. +ey had higher prevalence of atrial fi-
brillation, E/e’, and lower eGFR, tendency of older age,
lower eGFR, e’, and higher LA volume index and E/e’
without significance (Table 2).
3.3. Serial Changes in LV Filling Pressure, LA Volume, and
Stroke Volume. At baseline, E/e’ and LA volume index were
9.0± 3.5 and 30.5± 12.5mL/m2, respectively. One day after
the procedure, these values significantly increased to
11.4± 4.0 and 32.5± 12.1mL/m2, respectively, due to in-
creased LV filling from occlusion of a left-to-right shunt. LV
stroke volume increased from 52.1± 11.2mL to
61.5± 19.4mL the day after the procedure. At one-year
Table 1: Baseline clinical characteristics and echocardiographic measurements in patients with ASD.
Variable (n� 78) Parameter
Age, years 49.8± 15.0
Female, n (%) 51 (65)
Body mass index, kg/m2 22.4± 3.0
Systolic blood pressure, mmHg 116.5± 15.7
Blood urea nitrogen, mg/dL 15.1± 4.4
Creatinine, mg/dL 0.75± 0.16
eGFR, mL/min/1.73m2 99.8± 18.8
Atrial fibrillation, n (%) 6 (8)
LV mass index, g/m2 63.3± 16.3
LA volume index, mL/m2 30.5± 12.5
LV ejection fraction, % 66.1± 6.4
Stroke volume, mL 52.1± 11.2
TRV, m/sec 2.73± 0.48
PASP, mmHg 37.0± 12.3
PVR, Wood unit 1.47± 0.31
e’, cm/s 9.3± 3.2
E/e’ 9.0± 3.5
More than single defects, n (%) 4 (5)
ASD maximal defect diameter, mm 20.2± 6.0
ASD defect area, cm2 2.57± 1.52
ASD device diameter, mm 23.8± 6.4
Qp/Qs ratio 2.52± 0.85
Procedure guidance by TEE/ICE 64/14
Amplatzer, Abbott/Cocoon, Vascular Innovations/Figulla Flex II, Occlutech/Helex, Gore 41/33/3/1
ASD, atrial septal defect; e’, early diastolic septal mitral annular velocity; E/e’, ratio of early mitral inflow velocity to e’; ICE, intracardiac echocardiography;
LA, left atrial; LV, left ventricular; PASP, pulmonary arterial systolic pressure; PVR, pulmonary vascular resistance; TEE, transesophageal echocardiography;
TRV, tricuspid regurgitant velocity.
Device closure of ASD secundum





TTE (n = 39)
Exclusion
Exclusion
Patients with ESRD (n = 1)(i)
Patients without Doppler data before or
immediate after closure (n = 7) 
(ii)
Follow-up loss within 1year(i)
No one-year follow-up TTE (n = 39)(ii)
Figure 1: Schematic diagram of study patient selection process. ASD, atrial septal defect; ESRD, end-stage renal disease; TTE, transthoracic
echocardiography; TEE, transesophageal echocardiography; ICE, intracardiac echocardiography.
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follow-up, E/e’ and LA volume index decreased by 9.8± 3.0
and 27.8± 8.6mL/m2, which was accompanied by a further
increase in LV stroke volume (Figure 2). Immediate E/e’
changes after device closure (ΔE/e’-immediate) were sig-
nificantly correlated with immediate LA volume index
change (r� 0.424; P< 0.001). ASD area, maximal defect
diameter, and implanted device diameter were significantly
correlated with ΔE/e’-immediate but not with age. Higher
TRV and lower baseline E/e’ were correlated with ΔE/e’-
immediate (Table 3). In multivariate analysis, TRV and
baseline E/e’ were related to ΔE/e’-immediate.
3.4. SerialChanges inPulmonaryArterialPressureafterDevice
Closure. Of the 78 patients enrolled in the study, in two
patients, pre- or post-TRV were not measurable and 39 un-
derwent TTE at one-year follow-up. +e average PASP de-
creased approximately −6.15± 11.6mmHg immediately after
closure, but some patients (n� 21; 28%) paradoxically exhibited
increase in PASP. Patients with immediately increased PASP
were older, with lower eGFR, LV ejection fraction, and e’ and
higher LA volume index (Table 4). In multivariate analysis for
increased PASP-immediate, LV ejection fraction was signifi-
cantly related to PASP increase immediately after closure.
When serially followed, these patients also showed serially
decreased PASP one-year later below the baseline level, similar
to patients with initially decreased PASP (Figure 3). In patients
with immediately increased PASP, accompanying increase in
LA size was significantly blunted compared to decreased PASP
group (Figure 4).
4. Discussion
According to our study results, we found some patients
underwent new-onset atrial fibrillation and took diuretics
within one-year after device closure. In addition, some
patients who underwent device closure of ASD exhibited
immediate PASP elevation even after transpulmonary ar-
terial flow was reduced by blocking left-to-right shunt flow.
+is finding may be from immediately elevated pulmonary
capillary wedge pressure due to increased LV filling flow to
the noncompliant left ventricle or volume overload to the
noncompliant left atrium (perhaps from not only the
muscular part but also the device-covered noncompliant
part) [9]. +is speculation was supported by our findings
that impaired LV relaxation (as represented by lower e’) and
systolic function, and higher LA volume index was found in
the initial increased PASP group. +is finding was more
predominant in older patients with lower eGFR, suggesting
that these patients need peri-interventional preload reducing
medication, especially those with impaired diastolic function
and larger LA size. When elevated LV filling pressure
measured by E/e’ was seen after device closure, larger defect
size was more related to LV filling pressure elevation. +us,
especially in patients scheduled to close a larger defect,
physicians should be cautious to avoid postinterventional
pulmonary edema or exertional dyspnea aggravation. When
considering the poor correlation between delta PASP ele-
vation and delta E/e’ elevation after device closure, increased
PASP would be contributed by not only elevated LV filling
pressure [10] but also LA noncompliance, which is also
contributed by the device itself in the LA septum. An im-
mediate increase in E/e’ was significantly correlated with
increase in LA volume index. However, at one-year follow-
up, decreased LV filling pressure was accompanied by de-
creased LA volume index. When examining serial changes at
one-year follow-up, we found that all patients showed de-
creased PASP below the baseline level regardless of the
immediate PASP response, even in the paradoxically in-
creased PASP group. +us, despite the concern of device
closure in older patients with renal dysfunction, these
findings support that long-term hemodynamic response
Table 2: Comparisons between groups according to new-onset atrial fibrillation after device closure and diuretics use.











Age, years 60.0± 10.5 47.9± 14.9 0.113 58.8± 13.7 49.2± 15.0 0.124
Female, n (%) 2 (50) 45 (66) 0.509 3 (60) 48 (66) 0.794
Past history of AF, n (%) 4 (80) 2 (3) <0.001
eGFR, mL/min/1.73m2 90.0± 10.6 102.8± 17.4 0.085 80.8± 14.1 101.2± 18.4 0.018
Maximal defect diameter,
mm 23.0± 5.9 20.4± 6.0 0.308 20.0± 4.7 20.2± 6.2 0.886
Defect area, mm2 298.1± 110.8 262.1± 155.8 0.433 264.9± 151.4 256.5± 153.5 0.975
Device diameter, mm 26.0± 3.7 24.0± 6.5 0.491 22.8± 4.6 23.9± 6.5 0.779
LV mass index, g/m2 65.9± 17.5 62.8± 16.5 0.525 55.6± 14.4 63.9± 16.4 0.295
LA volume index, mL/m2 35.8± 6.5 28.1± 9.3 0.065 39.4± 20.4 29.9± 11.7 0.205
LV ejection fraction, % 62.3± 4.3 66.3± 6.6 0.198 65.4± 5.3 66.2± 6.5 0.772
Stroke volume, mL 51.6± 9.4 53.1± 10.7 0.832 40.7± 14.9 53.0± 10.5 0.038
TRV, m/sec 2.63± 0.36 2.72± 0.49 0.765 2.89± 0.56 2.72± 0.48 0.004
PASP, mmHg 36.8± 4.8 36.3± 12.6 0.549 45.5± 12.7 36.4± 12.2 0.306
PVR, Wood unit 1.24± 0.43 1.45± 0.27 0.336 1.91± 0.41 1.44± 0.28 0.088
e’, cm/s 8.8± 3.5 9.3± 3.3 0.787 8.9± 1.7 9.3± 3.3 0.974
E/e’ 10.7± 6.9 8.5± 3.0 0.681 11.5± 3.1 8.8± 3.4 0.038
AF, atrial fibrillation; see abbreviations in Table 1. ∗Patients with pre-existing AF were excluded; †Mann–Whitney test for nonparametric comparisons.














Preclosure Immediate after One-year later
1 year f/u [N = 39]





















Preclosure Immediate after One-year later
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Preclosure Immediate after One-year later
1 year f/u [N = 34]
Immediate f/u only [N = 69]
(d)
Figure 2: Serial changes in E/e’ (a), left atrial (LA) volume index (b), tricuspid regurgitant (TR) velocity (c), and left ventricular (LV) stroke
volume (d) from preclosure to one-year follow-up (n� 39). Blue dotted line represents comparisons between preclosure state and im-
mediately after (one-day after closure) follow-up only (n� 78). Bars represent 95% confidence intervals.
Table 3: Correlations of immediate E/e’ changes after device closure of an ASD.
Variable Pearson’s correlation coefficient (r value) P value
Age, years 0.039 0.742
Male −0.118 0.331
Body mass index, m2 −0.168 0.123
Systolic blood pressure, mmHg −0.042 0.738
Blood urea nitrogen, mg/dL 0.112 0.338
Creatinine, mg/dL 0.183 0.115
eGFR, mL/min/1.73m2 −0.110 0.349
ASD maximal defect diameter, mm 0.248 0.032
ASD defect area, cm2 0.309 0.008
ASD device diameter, mm 0.248 0.033
Qp/Qs ratio 0.217 0.103
LV mass index, g/m2 0.080 0.519
LA volume index, mL/m2 −0.078 0.509
LV ejection fraction, % 0.191 0.103
Stroke volume, mL −0.137 0.251
TRV, m/sec 0.332 0.004
Preclosure E/e’ −0.359 0.002
Preclosure Ed −0.227 0.055
ΔLA volume index-immediate 0.424 <0.001
Immediate LV Ed 0.480 <0.001
ASD, atrial septal defect; e’, early diastolic septal mitral annular velocity; Ed, end-diastolic elastance; E/e’, ratio of early mitral inflow velocity to e’; eGFR,
estimated glomerular filtration rate; LA, left atrial; LV, left ventricular; TRV, tricuspid regurgitant velocity.
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would be favorable in older patients.+erefore, with optimal
preload reduction and volume control during and imme-
diately after the procedure, device closure of ASD can be
recommended even in vulnerable patients [11].
+is study has some limitations. Although we found a
significant proportion of patients underwent paradoxi-
cally increase in PASP, especially in older patients, with
renal dysfunction, impaired LV relaxation, and larger LA,
the contribution of the device on the LA side could not be
fully determined. We could only assume that, with larger
LA and marginal compliance, adding a prosthesis may
worsen LA compliance. Although we could not find any
difference in device type, future studies are warranted to
determine how to reduce worsening LA compliance when
selecting device size, device type, and deployment
method.
Table 4: Comparison between patients with increased PASP and decreased PASP immediately after device closure of ASDs∗ .
Variable PASP decrease(n� 55)
PASP increase
(n� 21) P value
Age, years 47.7± 14.4 56.4± 15.2 0.022
Female, n (%) 36 (66) 14 (67) 0.921
Body surface area, m2 1.62± 0.14 1.57± 0.18 0.288
Body mass index, kg/m2 22.3± 2.9 22.3± 3.1 0.986
Systolic blood pressure, mmHg 116.7± 13.7 115.1± 19.7 0.027
Atrial fibrillation, n (%) 4 (7) 2 (10) 0.745
Blood urea nitrogen, mg/dL 14.4± 3.7 16.7± 5.8 0.046
Creatinine, mg/dL 0.74± 0.15 0.80± 0.20 0.168
eGFR, mL/min/1.73m2 102.6± 17.4 91.3± 20.3 0.018
Maximal defect diameter, mm 20.1± 6.2 21.1± 5.7 0.522
Defect area, mm2 253.0± 144.1 263.5± 156.4 0.794
Device diameter, mm 23.6± 6.5 25.0± 5.9 0.411
Qp/Qs ratio 2.46± 0.82 2.79± 0.95 0.214
LV mass index, g/m2 62.6± 14.1 64.4± 21.3 0.673
LA volume index, mL/m2 29.0± 12.5 35.4± 11.7 0.046
LV ejection fraction, % 67.4± 5.9 63.4± 7.0 0.015
Stroke volume, mL 52.4± 11.2 51.9± 11.7 0.869
TRV, m/sec 2.83± 0.46 2.48± 0.45 0.004
PASP, mmHg 39.2± 12.7 31.6± 9.6 0.016
PVR, Wood unit 1.49± 0.27 1.42± 0.42 0.425
e’, cm/s 9.8± 3.0 7.7± 3.4 0.013
E/e’ 8.65± 3.29 10.10± 3.94 0.120
Amplatzer, Abbott/Cocoon, Vascular Innovations/Figulla Flex II, Occlutech/
Helex, Gore 29/23/3/0 10/10/0/1 0.266
∗ In two patients, pre- or post-TRV were not measurable. ASD, atrial septal defect; e’, early diastolic septal mitral annular velocity; E/e’, ratio of early mitral
inflow velocity to e’; eGFR, estimated glomerular filtration rate; LA, left atrial; LV, left ventricular; PASP, pulmonary arterial systolic pressure; PVR,
pulmonary vascular resistance; TRV, tricuspid regurgitant velocity.
P = 0.002P = 0.003
P = 0.025
P < 0.001
1 year f/u [N = 11]














Preclosure Immediate after One-year later
(a)
1 year f/u [N = 27]
Immediate f/u only [N = 55]
P = 0.531P < 0.001














Preclosure Immediate after One-year later
(b)
Figure 3: Serial changes in pulmonary arterial systolic pressure (PASP) from preclosure stage to one-year follow-up by immediate PASP
response group: (a) immediately increased PASP group; (b) immediately decreased PASP group. Blue dotted line represents comparisons
between preclosure state and immediately after (one-day after closure) follow-up only. Bars represent 95% confidence intervals.
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5. Conclusions
In older patients with impaired LV relaxation, systolic
dysfunction, renal dysfunction, or larger LA size, PASP
could paradoxically increase after device closure of ASD
due to the immediate volume overload to a noncompliant
left ventricle and left atrium. +erefore, periprocedural
preload manipulation, such as diuretics, is recommended
in patients with these risk factors who are scheduled to
close a larger defect. However, after the immediate
periprocedural period, TRV, LA volume index, and E/e’
continuously decrease, suggesting the favorable effects of
ASD closure even in these high-risk patients. +e risk for
significant symptoms of heart failure is small with due
precautions as none of the patients in this cohort ex-
perienced any.
Abbreviations
ASD: Atrial septal defect
E: Peak early diastolic mitral inflow velocity
e’: Peak early diastolic mitral annular velocity




LVOT: LV outflow tract
PASP: Pulmonary arterial systolic pressure
TEE: Transesophageal echocardiography
TTE: Transthoracic echocardiography
TRV: Tricuspid regurgitant velocity
2D: Two dimensional
3D: +ree dimensional.
P = 0.329P = 0.260
P = 0.824
P = 0.114
1 year f/u [N = 10]
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P < 0.001
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P = 0.290P = 0.022
P = 0.533
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Preclosure Immediate after One-year later
(d)
Figure 4: Serial changes in E/e’, left atrial (LA) volume index, tricuspid regurgitant (TR) velocity, and left ventricular (LV) stroke volume
from preclosure stage to one-year follow-up in (a, b) immediately increased PASP group and (c, d) immediately decreased PASP group. Blue
dotted line represents comparisons between preclosure state and immediately after (one-day after closure) follow-up only. Bars represent
95% confidence intervals.
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